Work

Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL)

Year: 2008

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v112.11.3.3

Authors: Jonathan W. Friedberg, Jeff Sharman, Julia Schaefer-Cutillo, Patrick B. Johnston, Sven De Vos, Ann LaCasce, John P. Leonard, Larry D. Cripe, Rajni Sinha, Stephanie A. Gregory, John Sweetenham, Julie M. Vose, Ann M Lowe, R. Levy, Margaret A. Shipp

Institutions: University of Rochester Medicine, University of Rochester, Stanford University, Mayo Clinic, University of California, Los Angeles, Dana-Farber Cancer Institute, Weill Cornell Medicine, Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Emory University, Rush University Medical Center, Cleveland Clinic, Rigel (United States)

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2563685161

FWCI: 6.331

Cites:

Cited by: 29

Related to: 10